Prevent preclinical drug development program: preclinical efficacy and intermediate endpoint biomarkers - base contract. Period of performance: 1/25/2019 - 1/24/2024
Ended Awarded Last action
- Contract number
- 75N91019D00014
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 1 $4,863 obligated
Award facts
- Opportunity
-
- PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing Pre-Solicitation · N01CN7701918 · Posted Apr 19, 2018
- PREVENT Cancer Preclinical Drug Development Program Award Notice · Posted May 7, 2018
- Combined order value
- $4,863 Current and potential, with all options
- Last date to order 100% complete
- IDV ceiling <1% used
- $74,995,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Task orders
| Task order | Ordering agency | Obligated | Awarded |
|---|---|---|---|
| Prevent contract orientation & kick-off meeting contract#: 75N91019D00015 PP: 1/25/2019 to 2/24/2019 | National Cancer Institute (NIH) | $4,863 |
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91019D00014?
75N91019D00014 was awarded to Sri International by National Cancer Institute (National Institutes of Health) on January 24, 2019.
How much is contract 75N91019D00014 worth?
Orders under 75N91019D00014 have obligated $4,863. 75N91019D00014's own ceiling is $74,995,000.
How many orders have been placed under contract 75N91019D00014?
1 order has been placed under 75N91019D00014, the latest on January 24, 2019.
Who can order from contract 75N91019D00014?
75N91019D00014 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91019D00014 part of a contract vehicle?
Yes. 75N91019D00014 is part of PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019D00014 competed?
The extent of competition for 75N91019D00014 was full and open competition. The government received 9 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV